do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline for type 2 diabetes management The Role of DPP-4 Inhibitors

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression

Practical Considerations Several practical factors affect GLP-1 medication use

At baseline, participants in the GLP-1 RA group had a preserved eGFR compared with those in the SGLT2i group and were less likely to have a diagnosis of hypertension, IHD and heart failure

Tirzepatide was approved by the FDA for the treatment of diabetes in May 2022 and a few months later in the European Union, Canada and Australia

As a Functional Diagnostic Nutrition Practitioner (FDNP) , I am always expanding my knowledge of aging and metabolic health

however, for some people with obesity a pharmacotherapy treatment option like Saxenda may be needed to help them with chronic weight management," said Dr